XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Stockholders’ Deficit (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Stockholders’ Deficit [Abstract] |
Schedule of Compensation Expense Related Restricted Stock Awards | The table below summarizes the compensation expense related to the Company’s restricted stock awards for the six months ended June 30:
|  | 2024 |  |  | 2023 |
Directors |  |  |  |  |  |
February 23, 2023: 168,419 share grant of common stock |  | $ | 70,000 |  |  | $ | - |
Consultants |  |  |  |  |  |  |  |
October 20, 2021: 17,274 share grant for common stock |  |  | - |  |  |  | 146,000 |
October 22, 2021: 8,637 share grant for common stock |  |  | - |  |  |  | 62,000 |
October 26, 2021: 17,274 share grant for common stock |  |  | - |  |  |  | 122,000 |
Employees |  |  |  |  |  |  |  |
June 19, 2023; 675,058 share grant of common stock |  |  | 278,000 |  |  |  | 38,000 |
April 4, 2022: 166,667 share grant for common stock |  |  | - |  |  |  | 395,000 |
Stock-based compensation expense reversal for April 4, 2022 grant |  |  | - |  |  |  | (1,910,000 | )
Other |  |  |  |  |  |  |  |
Officer contributed capital |  |  | - |  |  |  | 126,000 |
|  | $ | 348,000 |  |  | $ | (1,021,000 | )
Schedule of Warrants Transactions | Transactions involving warrants are as follows for the six months ended June 30, 2024:
|  | Number of Shares |  |  | Weighted Average Strike Price/Share |  |  | Weighted Average Remaining Contractual Term (Years) |  |  | Weighted Average Grant Date Fair Value |  |  | Weighted Average Intrinsic Value |
Outstanding – December 31, 2023 |  |  | 1,844,781 |  |  | $ | 9.84 |  |  |  | 1.39 |  |  | $ | 5.81 |  |  | $ | 1.19 |
Granted |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | 165,622 |  |  |  | 0.006 |  |  |  | 0.75 |  |  |  | 9.06 |  |  |  | 1.48 |
Expired |  |  | 1,652,851 |  |  |  | 10.98 |  |  |  | - |  |  |  | 7.55 |  |  |  | - |
Outstanding – June 30, 2024 |  |  | 26,308 |  |  |  | 0.006 |  |  |  | 0.50 |  |  |  | 0.14 |  |  |  | 1.18 |
Vested and exercisable – June 30, 2024 |  |  | 26,308 |  |  |  | 0.006 |  |  |  | 0.50 |  |  |  | 0.14 |  |  |  | 1.18 |
Unvested and non-exercisable – June 30, 2024 |  |  | - |  |  | $ | - |  |  |  | - |  |  | $ | - |  |  | $ | - |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration